专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07563769B2 FGF variants and methods for use thereof 有权
标题翻译： FGF变体及其使用方法
公开(公告)号：US07563769B2
公开(公告)日：2009-07-21
申请号：US10982514
申请日：2004-11-05
申请人： Oren Bogin , Avner Yayon
发明人： Oren Bogin , Avner Yayon
IPC分类号： C07K14/475 , C07K14/50 , A61K38/18
CPC分类号： A61K38/1825 , A61K38/22 , C07K14/50 , C07K14/501 , C07K14/503 , C07K14/575 , C12N5/0655 , C12N5/0658 , C12N2501/115 , C12N2506/1346
摘要： The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
摘要翻译：本发明提供证明增强的受体亚型特异性和/或亲和力的成纤维细胞生长因子变体。优选的实施方案包括具有增强活性的两种变体，其作为改善的激动剂和具有降低的作为拮抗剂的活性的变体。提供了利用优选的FGF变体在制备用于治疗骨骼障碍（包括骨骼发育不良，骨质疏松症和增强骨折愈合和软骨愈合过程）的药物中的方法。

2. 发明授权

US08609823B2 FGF-9 variants and methods for use thereof 有权
标题翻译： FGF-9变体及其使用方法
公开(公告)号：US08609823B2
公开(公告)日：2013-12-17
申请号：US13347823
申请日：2012-01-11
申请人： Oren Bogin , Avner Yayon
发明人： Oren Bogin , Avner Yayon
IPC分类号： A61K38/18
CPC分类号： A61K38/1825 , A61K38/22 , C07K14/50 , C07K14/501 , C07K14/503 , C07K14/575 , C12N5/0655 , C12N5/0658 , C12N2501/115 , C12N2506/1346
摘要： The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
摘要翻译：本发明提供证明增强的受体亚型特异性和/或亲和力的成纤维细胞生长因子变体。优选的实施方案包括具有增强活性的两种变体，其作为改善的激动剂和具有降低的作为拮抗剂的活性的变体。提供了利用优选的FGF变体在制备用于治疗骨骼障碍（包括骨骼发育不良，骨质疏松症和增强骨折愈合和软骨愈合过程）的药物中的方法。

3. 发明申请

US20120214739A1 FGF VARIANTS AND METHODS FOR USE THEREOF 有权
标题翻译： FGF变量及其使用方法
公开(公告)号：US20120214739A1
公开(公告)日：2012-08-23
申请号：US13347823
申请日：2012-01-11
申请人： Oren Bogin , Avner Yayon
发明人： Oren Bogin , Avner Yayon
IPC分类号： A61K38/18 , C07H21/04 , A61P19/08 , C07K14/50
CPC分类号： A61K38/1825 , A61K38/22 , C07K14/50 , C07K14/501 , C07K14/503 , C07K14/575 , C12N5/0655 , C12N5/0658 , C12N2501/115 , C12N2506/1346
摘要： The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
摘要翻译：本发明提供证明增强的受体亚型特异性和/或亲和力的成纤维细胞生长因子变体。优选的实施方案包括具有增强活性的两种变体，其作为改善的激动剂和具有降低的作为拮抗剂的活性的变体。提供了利用优选的FGF变体在制备用于治疗骨骼障碍（包括骨骼发育不良，骨质疏松症和增强骨折愈合和软骨愈合过程）的药物中的方法。

4. 发明授权

US08119783B2 FGF variants and methods for use thereof 有权
标题翻译： FGF变体及其使用方法
公开(公告)号：US08119783B2
公开(公告)日：2012-02-21
申请号：US12416435
申请日：2009-04-01
申请人： Oren Bogin , Avner Yayon
发明人： Oren Bogin , Avner Yayon
IPC分类号： C12N15/11 , C12N15/12 , A61K38/18
CPC分类号： A61K38/1825 , A61K38/22 , C07K14/50 , C07K14/501 , C07K14/503 , C07K14/575 , C12N5/0655 , C12N5/0658 , C12N2501/115 , C12N2506/1346
摘要： The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
摘要翻译：本发明提供证明增强的受体亚型特异性和/或亲和力的成纤维细胞生长因子变体。优选的实施方案包括具有增强活性的两种变体，其作为改善的激动剂和具有降低的作为拮抗剂的活性的变体。提供了利用优选的FGF变体在制备用于治疗骨骼障碍（包括骨骼发育不良，骨质疏松症和增强骨折愈合和软骨愈合过程）的药物中的方法。

5. 发明申请

US20050148511A1 FGF variants and methods for use thereof 有权
标题翻译： FGF变体及其使用方法
公开(公告)号：US20050148511A1
公开(公告)日：2005-07-07
申请号：US10982514
申请日：2004-11-05
申请人： Oren Bogin , Avner Yayon
发明人： Oren Bogin , Avner Yayon
IPC分类号： A61K38/17 , A61K38/18 , C07H21/04 , C07K20060101 , C07K14/50 , C07K14/715
CPC分类号： A61K38/1825 , A61K38/22 , C07K14/50 , C07K14/501 , C07K14/503 , C07K14/575 , C12N5/0655 , C12N5/0658 , C12N2501/115 , C12N2506/1346
摘要： The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
摘要翻译：本发明提供证明增强的受体亚型特异性和/或亲和力的成纤维细胞生长因子变体。优选的实施方案包括具有增强活性的两种变体，其作为改善的激动剂和具有降低的作为拮抗剂的活性的变体。提供了利用优选的FGF变体在制备用于治疗骨骼障碍（包括骨骼发育不良，骨质疏松症和增强骨折愈合和软骨愈合过程）的药物中的方法。

6. 发明申请

US20090247462A1 FGF VARIANTS AND METHODS FOR USE THEREOF 有权
标题翻译： FGF变量及其使用方法
公开(公告)号：US20090247462A1
公开(公告)日：2009-10-01
申请号：US12416435
申请日：2009-04-01
申请人： Oren Bogin , Avner Yayon
发明人： Oren Bogin , Avner Yayon
IPC分类号： A61K38/18 , C07K14/50 , C07H21/04
CPC分类号： A61K38/1825 , A61K38/22 , C07K14/50 , C07K14/501 , C07K14/503 , C07K14/575 , C12N5/0655 , C12N5/0658 , C12N2501/115 , C12N2506/1346
摘要： The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.
摘要翻译：本发明提供证明增强的受体亚型特异性和/或亲和力的成纤维细胞生长因子变体。优选的实施方案包括具有增强活性的两种变体，其作为改善的激动剂和具有降低的作为拮抗剂的活性的变体。提供了利用优选的FGF变体在制备用于治疗骨骼障碍（包括骨骼发育不良，骨质疏松症和增强骨折愈合和软骨愈合过程）的药物中的方法。

7. 发明授权

US07288406B2 Active variants of FGF with improved specificity 有权
标题翻译：具有改善特异性的FGF的活性变体
公开(公告)号：US07288406B2
公开(公告)日：2007-10-30
申请号：US10424955
申请日：2003-04-29
申请人： Oren Bogin , Rivka Adar , Avner Yayon
发明人： Oren Bogin , Rivka Adar , Avner Yayon
IPC分类号： C07K14/50 , A61K38/18 , C12N15/63 , C12N15/18
CPC分类号： C07K14/50
摘要： The present invention provides active fibroblast growth factor variants demonstrating enhanced receptor subtype specificity. The preferred novel variants retain binding to FGF Receptor Type 3 (FGFR3) triggering intracellular downstream mechanisms leading to activation of a biological response. Methods of utilizing preferred FGF mutants in preparation of medicaments for the treatment of malignancies and skeletal disorders including osteoporosis and enhancing fracture healing and wound healing processes are provided.
摘要翻译：本发明提供了表现出增强的受体亚型特异性的活性成纤维细胞生长因子变体。优选的新型变体保留结合FGF受体3型（FGFR3），引发细胞内下游机制导致生物反应的激活。提供了利用优选的FGF突变体制备用于治疗恶性肿瘤和骨骼疾病（包括骨质疏松症和增强骨折愈合和伤口愈合过程）的药物的方法。

8. 发明授权

US07264946B2 Thermoanaerobacter brockii alcohol dehydrogenase promoter for expression of heterologous proteins 有权
标题翻译：用于表达异源蛋白的热厌氧杆菌醇脱氢酶启动子
公开(公告)号：US07264946B2
公开(公告)日：2007-09-04
申请号：US10389821
申请日：2003-03-18
申请人： Oren Bogin , Avner Yayon , Moshe Peretz , Yigal Burstein
发明人： Oren Bogin , Avner Yayon , Moshe Peretz , Yigal Burstein
IPC分类号： C12N15/00 , C12N5/10 , C12P21/02 , C07H21/04
CPC分类号： C12N9/0004 , C12N15/67
摘要： The present invention discloses the isolation and use of a specific bacterial promoter region suitable for use in constructs for the high level production of heterologous proteins. This promoter is derived from the bacterial gene encoding for alcohol dehydrogenase, in particular the alcohol dehydrogenase genes isolated from the thermophilic bacterial strain T. brockii and the mesophilic bacterial strain Clostridium beijerinckii. It is now disclosed that using either the intact promoter region or certain specific fragments consisting of at least a 88 bp DNA sequence in the upstream untranslated region of the bacterial alcohol dehydrogenase gene, operatively linked to the nucleic acid sequences encoding a heterologous protein, and insertion into a DNA plasmid or any other suitable vector system, heterologous genes can be expressed in high levels in host cells. Heterologous proteins or peptides can be expressed constitutively at high levels. The proteins are obtained in their active folded form.
摘要翻译：本发明公开了分离和使用适用于高产量异源蛋白质的构建体的特异性细菌启动子区域。该启动子源自编码醇脱氢酶的细菌基因，特别是从嗜热细菌菌株T. brockii和嗜温细菌菌株Clostridium beijerinckii分离的醇脱氢酶基因。现在公开的是，使用完整启动子区域或由细菌醇脱氢酶基因的上游非翻译区域中至少88bp DNA序列组成的某些特异性片段，与编码异源蛋白质的核酸序列可操作地连接，并插入进入DNA质粒或任何其他合适的载体系统中，异源基因可以在宿主细胞中以高水平表达。异源蛋白或肽可以以高水平组成型表达。以活性折叠形式获得蛋白质。

9. 发明授权

US08618258B2 Freeze-dried fibrin matrices and methods for preparation thereof 有权
标题翻译：冻干纤维蛋白基质及其制备方法
公开(公告)号：US08618258B2
公开(公告)日：2013-12-31
申请号：US13465452
申请日：2012-05-07
申请人： Avner Yayon , Malkit Azachi , Micha Gladnikoff
发明人： Avner Yayon , Malkit Azachi , Micha Gladnikoff
IPC分类号： A61K35/14
CPC分类号： A61K9/0024 , A61F2/30756 , A61K9/2063 , A61K31/727 , A61K31/728 , A61K35/12 , A61K38/1825 , A61L27/225 , A61L27/3852 , A61L27/56 , C07K14/75 , C12N5/0068 , C12N5/0655 , C12N2533/56
摘要： Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.
摘要翻译：通过在血液蛋白质形成的多孔冷冻干燥的纤维蛋白基质中在疾病或损伤部位植入组织来治疗患病或损伤的组织的方法。蛋白质包括纤维蛋白原，其通过凝血酶的作用以不同的浓度切割，足以切割纤维蛋白原和因子XIII。该基质具有少于10％的残留水分，没有外源抗纤维蛋白溶解剂，纤溶酶原和有机螯合剂。或者，血浆蛋白质包含没有纤溶酶原的部分纯化的血浆蛋白质。

10. 发明申请

US20120328699A1 METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS 审中-公开
标题翻译：用于治疗骨质疏松症的方法和组合
公开(公告)号：US20120328699A1
公开(公告)日：2012-12-27
申请号：US13006129
申请日：2011-01-13
申请人： Myriam Golembo , Avner Yayon
发明人： Myriam Golembo , Avner Yayon
IPC分类号： A61K35/00 , A61P19/00 , A61K9/00
CPC分类号： A61K35/33 , A61K35/12 , A61K38/2242 , A61K48/00 , A61K2035/128 , C07K14/58 , C07K14/61 , C07K2319/02
摘要： The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP).
摘要翻译：本发明涉及通过向患者施用包含治疗有效量的至少一种C型利尿钠肽（CNP）的组合物来治疗骨骼发育不良的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式